NASDAQ:ADAP   Adaptimmune Therapeutics plc
Double Bottom at 3.60...long term support. Breaking through the wedge now. Clinical trial results in May.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.